Skip to main content
SpringerLink
Log in

United Kingdom: Neuroleptic Relapse Prevention

  • Conference paper
Guidelines for Neuroleptic Relapse Prevention in Schizophrenia

  • 31 Accesses

Abstract

Antipsychotic drug treatment is administered over, a long term principally to reduce the risk of acute relapse, or at least to postpone such episodes (Davis 1975). Attempts to produce clear guidelines or recommendations for relapse prevention may currently be confounded by our scant knowledge regarding basic issues such as the relative value of oral and depot preparations in this regard; whether particular drugs, classes of drugs or dose regimes have specific advantages such as fewer side effects or more effective relapse prevention; whether there is greater prophylactic value with early treatment; and whether the benefits of maintenance drug treatment persist indefinitely. The generation of individualised drug regimes will require more detailed information, primarily the identification of the variables predicting both short- and long-term response to drug treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Andrews P, Hall JN, Smith RP (1976) A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. Br J Psychiatry 128:451–455

    Article  PubMed  CAS  Google Scholar 

  • Babiker IE (1987) Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic relapse. J Clin Psychiatry 48:94–97

    PubMed  CAS  Google Scholar 

  • Barnes TRE, Milavic G, Curson DA, Platt SD (1983) Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic outpatients: pimozide versus fluphenazine. Soc Psychiatry 18:193–199

    Article  PubMed  CAS  Google Scholar 

  • Ciompi L (1980) The natural history of schizophrenia in the long term. Br J Psychiatry 136:413–420

    Article  PubMed  CAS  Google Scholar 

  • Crammer J, Eccleston D (1989) A survey of the use of depot neuroleptics in a whole region. Psychiatr Bull 13:517–520

    Article  Google Scholar 

  • Crow TJ, McMillan JF, Johnson AL, Johnstone EC (1986) The Northwick Park Study of first episodes of schizophrenia. II. A randomized controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 148:120–127

    Article  PubMed  CAS  Google Scholar 

  • Curson DA, Barnes TRE, Bamber RWK, Platt SD, Hirsch SR, Duffy JC (1985) Long-term depot maintenance of chronic schizophrenic outpatients: the seven-year follow-up of the MRC fluphenazine/placebo trial. Br J Psychiatry 146:464–480

    Article  PubMed  CAS  Google Scholar 

  • Davis JM (1975) Overview: maintenance therapy in psychiatry. I. Schizophrenia. Am J Psychiatry 132:1237–1245

    PubMed  CAS  Google Scholar 

  • Davis JM (1988) Maintenance medication. In: Barnes TRE (ed) Depot neuroleptics: a consensus. Mediscript, London, p 47

    Google Scholar 

  • Eberhard G, Hellbom E (1986) Haloperidol decanoate and flupenthixol decanoate in schizophrenia. Acta Psychiatr Scand 7:255–262

    Article  Google Scholar 

  • Falloon IRH, Watts DC, Shepherd M (1978) A comparative controlled trial of pimozide and fluphenazine decanoate in continuation therapy of schizophrenia. Psychol Med 8:59–70

    Article  PubMed  CAS  Google Scholar 

  • Faraone SV, Brown WA, Laughren TP (1987) Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients. J Clin Psychiatry 48:151–154

    PubMed  CAS  Google Scholar 

  • Herz MI, Glazer W (1988) Intermittent medication in schizophrenia — preliminary results (Abstr). Schizophr Res 1:224

    Article  Google Scholar 

  • Herz MI, Melville C (1980) Relapse in schizophrenia. Am J Psychiatry 137:801–805

    PubMed  CAS  Google Scholar 

  • Hirsch SR, Jolley AG, Morrison E, McRink A, Wilson L (1990) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic out-patients: clinical and social outcome at two years (Abstr). Schizophr Res 3:40

    Article  Google Scholar 

  • Hogarty GE (1984) Depot neuroleptics: the relevance of psychosocial factors — a United States perspective. J Clin Psychiatry 45:36–42

    PubMed  CAS  Google Scholar 

  • Johnson DAW, Pasterski G, Ludlow JM, Street K, Taylor RDW (1983) The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 67:339–352

    Article  PubMed  CAS  Google Scholar 

  • Johnson DAW, Ludlow JM, Street K, Taylor RDW (1987) Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised outpatients with schizophrenia. Br J Psychiatry 151:634–638

    Article  PubMed  CAS  Google Scholar 

  • Jolley AG, Hirsch SR, McRink A, Manchanda R (1989) Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one-year follow-up. Br Med J 298:985–990

    Article  CAS  Google Scholar 

  • Kane JM (1987) Treatment of schizophrenia. Schizophr Bull 13:133–156

    PubMed  CAS  Google Scholar 

  • Kane JM, Smith JM (1982) Tardive dyskinesia: prevalence and risk factors, 1959–1979. Arch Gen Psychiatry 39:473–481

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Rifkin A, Quitkin F, Naya D, Ramos-Lorenzi J (1982) Fluphenazine versus placebo in patients with remitted, acute first episode schizophrenia. Arch Gen Psychiatry 39:70–73

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Rifkin A, Woerner M, Reardow G, Sarantakos S, Schiebel D, Ramos-Lorenzi J (1983) Low-dose neuroleptic treatment of outpatient schizophrenics. Arch Gen Psychiatry 40:893–896

    Article  PubMed  CAS  Google Scholar 

  • Kissling W, Möller HJ, Walter K, Wittmann B, Krueger R, Trenk D (1985) Double-blind comparison of haloperidol decanoate and fluphenazine decanoate. Effectiveness, side-effects, dosage and serum levels during a six-month treatment for relapse prevention. Pharmacopsychiatry 18:240–245

    Article  PubMed  CAS  Google Scholar 

  • Manchanda R, Hirsch SR (1986) Low-dose maintenance medication for schizophrenia (Editorial). Br Med J 293:515–516

    Article  CAS  Google Scholar 

  • McKane JP, Robinson ADT, Wiles DH, McCreadie RG, Stirling GS (1987) Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. Br J Psychiatry 151:333–336

    Article  PubMed  CAS  Google Scholar 

  • Marder SR, van Putten T, Mintz J, Lebell M, McKenzie J, May PR (1987) Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 44:518–521

    Article  PubMed  CAS  Google Scholar 

  • Prien RF, Cole JO, Belkin NF (1969) Relapse in chronic schizophrenics following abrupt withdrawal of tranquillizing medication. Br J Psychiatry 115:679–686

    Article  PubMed  CAS  Google Scholar 

  • Quitkin F, Rifkin A, Kane JM, et al. (1978) Long-acting oral drugs vs injectable antipsychotic drugs in schizophrenics, a one-year double-blind comparison in multiple-episode schizophrenics. Arch Gen Psychiatry 35:889–892

    Article  PubMed  CAS  Google Scholar 

  • Scottish Schizophrenia Research Group (1987) The Scottish first-episode schizophrenia study. Br J Psychiatry 150:331–333

    Article  Google Scholar 

  • Wistedt B (1981) A depot neuroleptic withdrawal study: a controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand 64:65–84

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. T. R. E. Barnes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. R. Hirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik und Poliklinik, Technischen Universität München, Ismaninger Straße 22, W-8000, München 80, Germany

    Werner Kissling

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Barnes, T.R.E., Hirsch, S.R. (1991). United Kingdom: Neuroleptic Relapse Prevention. In: Kissling, W. (eds) Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-86922-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-86922-8_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-53985-8

  • Online ISBN: 978-3-642-86922-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation